Avoid ‘Political Games’ Or Risk EMA Losing Most Of Its Staff, Italian Industry Head Warns

 
• By Ian Schofield
  
Generate a summary of this article
Listen to this article
Beta

Massimo Scaccabarozzi, president of Italy’s Farmindustria and Janssen Italy’s MD, warns that the EMA could lose almost all of its current staff if it moves to a country they do not want to go to, and has called for a shortlist of candidate countries to be drawn up.

EMA offices
Politics must play no role in choice of new EMA location, says Italian industry head

The head of the Italian pharmaceutical industry body, Farmindustria, has called on the EU to draw up a shortlist of countries bidding to host the European Medicines Agency after Brexit, saying that otherwise the selection process could be dominated by “political games,” with the EMA at risk of losing most of its staff if they don’t want to move to the new location.

Janssen Italy managing director and Farmindustria president Massimo Scaccabarozzi naturally enough feels the northern Italian city of Milan would be...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Italy

European First As Vertex’s CRISPR/Cas9 Gene Therapy Casgevy Gets English Funding

 
• By Eliza Slawther

Casgevy, the world’s first CRISPR gene editing therapy, is the second drug to be accepted onto a managed access scheme via England’s Innovative Medicines Fund, offering a new treatment for patients with transfusion-dependent beta thalassemia.

Another Funding Win For Chiesi In Europe As Scotland OKs Elfabrio

 
• By Eliza Slawther

Scotland’s health technology assessment body has agreed to reimburse Chiesi’s Elfabrio for Fabry disease, mirroring the decision from several other European countries – however, France turned down the rare disease drug, while Germany questioned its benefit.

Italy Probes Alleged Antitrust Deal Over Biosimilar Version Of Eye Drug Lucentis

 
• By Dean Rudge

Did Samsung Bioepis and Biogen choose early US access for their Lucentis biosimilar in exchange for postponing launch in other markets? That’s what Italy’s competition authority believes, as it investigates the biosimilar sponsors and originator companies Genentech and Novartis.

Final Funding Blow For J&J’s Spravato In England, Despite Reimbursement In 26 Other Countries

 
• By Eliza Slawther

J&J says it has “exhausted all current viable avenues” to get its antidepressant nasal spray Spravato reimbursed on England’s National Health Service, after NICE decided against re-appraising the drug following numerous funding rejections.

More from Europe

EU Biosimilar Filings, Opinions And Approvals

 
• By Saba Afreen

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

UK Expedites Cost Negotiations For Companies Conducting ATMP & Early Phase Trials

 
• By Neena Brizmohun

Companies dealing with commercial costings or contracts with the National Health Service for early phase clinical trials or trials of advanced therapy medicinal products should soon be able to conclude their negotiations more quickly.

How To Decarbonize Pharma R&D

 
• By Francesca Bruce

As the planet heats up and sea levels rise, the need to reduce carbon emissions is becoming ever more urgent. The life sciences industry is just one of many that are looking to cut the carbon it produces.